Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 2 | 2013 | 369 | 0.610 |
Why?
|
| Herpes Zoster | 1 | 2013 | 3 | 0.420 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 8 | 0.410 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 13 | 0.410 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 51 | 0.400 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 39 | 0.400 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 12 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 139 | 0.380 |
Why?
|
| Oseltamivir | 1 | 2011 | 1 | 0.380 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 5 | 0.370 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 18 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 67 | 0.360 |
Why?
|
| Influenza, Human | 1 | 2011 | 41 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2011 | 68 | 0.350 |
Why?
|
| Pandemics | 1 | 2011 | 201 | 0.330 |
Why?
|
| United States | 3 | 2013 | 1726 | 0.210 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 3 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 78 | 0.170 |
Why?
|
| Female | 6 | 2021 | 12677 | 0.160 |
Why?
|
| Adult | 4 | 2021 | 6584 | 0.150 |
Why?
|
| Middle Aged | 4 | 2021 | 7555 | 0.150 |
Why?
|
| Raltegravir Potassium | 1 | 2016 | 2 | 0.130 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2016 | 4 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2016 | 35 | 0.130 |
Why?
|
| Risk Factors | 2 | 2012 | 1942 | 0.130 |
Why?
|
| Humans | 6 | 2021 | 22848 | 0.120 |
Why?
|
| Male | 4 | 2021 | 12453 | 0.120 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 2 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2013 | 4 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2013 | 57 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 42 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2013 | 41 | 0.100 |
Why?
|
| Viral Load | 1 | 2013 | 65 | 0.100 |
Why?
|
| Child | 2 | 2016 | 990 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2012 | 20 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 127 | 0.090 |
Why?
|
| Women's Health | 1 | 2013 | 115 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 101 | 0.090 |
Why?
|
| Pregnancy | 1 | 2012 | 303 | 0.090 |
Why?
|
| Incidence | 1 | 2013 | 649 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 381 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 241 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 554 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 377 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 401 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 713 | 0.080 |
Why?
|
| Chicago | 1 | 2011 | 808 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2013 | 1528 | 0.070 |
Why?
|
| Adolescent | 1 | 2011 | 1775 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 47 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 138 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 112 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 295 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 102 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 254 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 272 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2016 | 7 | 0.030 |
Why?
|
| Aged | 1 | 2021 | 7669 | 0.020 |
Why?
|